Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 2/20 | 0.48 |
| ▸ | TERT | O14746 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | APAF1 | O14727 | 1/20 | 0.45 |
| ▸ | ELANE | P08246 | 2/20 | 0.40 |
| ▸ | KDM1A | O60341 | 7/20 | 0.40 |
| ▸ | EGFR | P00533 | 2/20 | 0.40 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.40 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6123011 | 0.79 | APP (0.48) | APPTERTKDM4EPOLBAPAF1 | |
| SCHEMBL8936155 | 0.78 | POLB (0.72) | KDM4ECYP3A4CYP2C19HIF1APOLB | |
| SCHEMBL3420261 | 0.78 | POLB (0.52) | KDM4ECYP3A4CYP2C19HIF1APOLB | |
| SCHEMBL2672333 | 0.76 | MAPT (0.53) | APPTERTPOLBAPAF1ELANE | |
| SCHEMBL24299673 | 0.76 | APP (0.63) | APPTERTKDM4EAPAF1ELANE | |
| SCHEMBL7424524 | 0.75 | CYP2C19 (0.49) | KDM4ECYP3A4CYP2C19HIF1APOLB | |
| SCHEMBL1600117 | 0.75 | KDM4E (0.49) | APPKDM4ECYP3A4CYP2C19HIF1A | |
| SCHEMBL3060777 | 0.75 | KDM4E (0.49) | KDM4ECYP3A4CYP2C19HIF1APOLB | |
| SCHEMBL5437258 | 0.75 | KDM4E (0.49) | KDM4ECYP3A4CYP2C19HIF1APOLB | |
| SCHEMBL5434270 | 0.75 | KDM4E (0.50) | KDM4ECYP3A4CYP2C19HIF1APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100482663-C | Novel fused triazolones and the uses thereof | ASTRAZENECA AB SE (SE) | 2009-04-29 | — | — | CN | disclosed |
| US-20070149560-A1 | Novel fused triazolones and the uses thereof | ASTRAZENECA AB (SE) | 2007-06-28 | — | — | US | disclosed |
| CN-1784401-A | Novel fused triazolones and uses thereof | ASTRAZENECA AB (SE) | 2006-06-07 | — | — | CN | disclosed |
| EP-1613625-A1 | NOVEL FUSED TRIAZOLONES AND THE USES THEREOF | AstraZeneca AB (SE) | 2006-01-11 | — | — | EP | disclosed |
| WO-2004081008-A1 | NOVEL FUSED TRIAZOLONES AND THE USES THEREOF | ASTRAZENECA AB (SE) | 2004-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149560-A1 | Novel fused triazolones and the uses thereof | TP53, BRCA1, KLK3 | APP 4794/4885TERT 230/4885KDM4E 3368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.